Stryker (NYSE: SYK) reported Q2 EPS of $2.81, $0.02 better than the analyst estimate of $2.79. Revenue for the quarter came in at $5.4 billion versus the consensus estimate of $5.4 billion.

GUIDANCE:

Stryker sees FY2024 EPS of $11.90-$12.10, versus the consensus of $11.93.

Based on our year-to-date performance and our positive outlook related to sustained procedural volumes and a healthy demand for our capital products, we now expect full year 2024 organic net sales growth(2) to be in the range of 9.0% to 10.0% with a favorable pricing impact of approximately 0.5%.

For earnings history and earnings-related data on Stryker (SYK) click here.